<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Articles Criticize Merck on Vioxx</title>
	<atom:link href="http://washingtonindependent.com/1655/articles-criticize-merck-on-vioxx/feed" rel="self" type="application/rss+xml" />
	<link>http://washingtonindependent.com/1655/articles-criticize-merck-on-vioxx</link>
	<description>National News in Context</description>
	<lastBuildDate>Sun, 04 Mar 2012 13:30:47 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
	<item>
		<title>By: medical device design</title>
		<link>http://washingtonindependent.com/1655/articles-criticize-merck-on-vioxx/comment-page-1#comment-201314</link>
		<dc:creator>medical device design</dc:creator>
		<pubDate>Sun, 12 Sep 2010 22:18:28 +0000</pubDate>
		<guid isPermaLink="false">http://www.washingtonindependent.com.php5-9.websitetestlink.com/?p=1655#comment-201314</guid>
		<description>In the first article, Bruce Psaty and Richard Kronmal of University of Washington found that in an April 2001 analysis of two trials of Vioxx for the prevention of Alzheimer’s disease, company officials found a three-fold risk of death in the patients who took the drug compared to those who took a sugar pill placebo. The three-fold risk was based on examining records of patients on the drug and those who had used it in the previous two years. &lt;br&gt;</description>
		<content:encoded><![CDATA[<p>In the first article, Bruce Psaty and Richard Kronmal of University of Washington found that in an April 2001 analysis of two trials of Vioxx for the prevention of Alzheimer’s disease, company officials found a three-fold risk of death in the patients who took the drug compared to those who took a sugar pill placebo. The three-fold risk was based on examining records of patients on the drug and those who had used it in the previous two years. </p>
]]></content:encoded>
	</item>
</channel>
</rss>

